变构抑制剂单药及联合靶向突变型EGFR的研究
本研究鉴定并研究了一种突变选择性EGFR变构抑制剂JBJ-04-125-02,单药可在体外和体内抑制细胞增殖及EGFRL858R/T790M/C797S信号。但EGFR二聚体形成增加限制疗效并导致耐药;奥希替尼可独特且显著增强JBJ-04-125-02与突变EGFR的结合,两药联合较任一单药增加凋亡、更有效抑制细胞生长并提高体外和体内疗效。
要点
- JBJ-04-125-02为突变选择性EGFR变构抑制剂,单药可抑制增殖及EGFRL858R/T790M/C797S信号。
- EGFR二聚体形成增加限制JBJ-04-125-02单药疗效并导致耐药。
- 奥希替尼增强JBJ-04-125-02与突变EGFR结合,联合较单药增加凋亡并提高体外和体内疗效。
核心结论
- 共价突变选择性ATP竞争性抑制剂与变构EGFR抑制剂联合可能是EGFR突变肺癌患者的有效治疗策略。
研究设计与样本
- 本研究鉴定并研究突变选择性EGFR变构抑制剂JBJ-04-125-02,开展体外和体内研究。
主要发现
- JBJ-04-125-02单药可在体外和体内抑制细胞增殖及EGFRL858R/T790M/C797S信号。
- EGFR二聚体形成增加限制JBJ-04-125-02疗效并导致耐药。
- 奥希替尼独特且显著增强JBJ-04-125-02与突变EGFR的结合。
- 奥希替尼联合JBJ-04-125-02较任一单药增加凋亡、更有效抑制细胞生长并提高体外和体内疗效。
临床怎么用
- 作者认为,共价突变选择性ATP竞争性抑制剂与变构EGFR抑制剂联合可能是EGFR突变肺癌患者的有效治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding. In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo. However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance. Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR. The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone. Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer. SIGNIFICANCE: The clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR. Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.This article is highlighted in the In This Issue feature, p. 813.
引用
- To C, Jang J, Chen T, et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019. PMID: 31092401. doi:10.1158/2159-8290.CD-18-0903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。